Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

Enhancing Patient Experience in Geriatric Oncology

23 giugno 2026 aggiornato da: Theodora Karnakis, Hospital Sirio-Libanes

Enhancing the Experience of Older Adults With Cancer Through a Comfort Menu and Cart for: Protocol of a Quasi-experimental, Before-and-after Study in a Tertiary Oncology Center

Approximately 60% of new cancer diagnoses and 70% of cancer-related deaths occur in adults aged 65 years and older, a population frequently affected by multimorbidity, frailty, sensory impairment, and treatment-related symptom burden. Outpatient oncology centers, although designed for efficient antineoplastic therapy delivery, are rarely adapted to the specific needs of older adults, and pragmatic, low-cost interventions to enhance patient experience and the clinical care journey remain scarce. The "comfort menu and cart," a non-pharmacological strategy initially developed for the emergency department, has shown promising effects on patient and staff experience, but has not been evaluated in the geriatric oncology setting.

Methods: This protocol describes a quasi-experimental, before-and-after, single-center study evaluating the implementation of a comfort menu and cart at the Oncology Center of Hospital Sírio-Libanês, a tertiary philanthropic hospital in São Paulo, Brazil. Patients aged 65 years and older receiving intravenous chemotherapy, supportive therapy, or evaluation of intercurrent symptoms during oncological treatment will be recruited over 12 months: six months pre-intervention and six months post-intervention, with 132 participants per phase and a total sample of 264 participants. All participants will undergo a comprehensive geriatric assessment, including G8, Charlson Comorbidity Index, Clinical Frailty Scale, Geriatric Depression Scale - 15-item version, Katz Index of Independence in Activities of Daily Living, Barthel Index of Activities of Daily Living, Lawton-Brody Instrumental Activities of Daily Living Scale, 10-point Cognitive Screener, and EuroQol 5-Dimension questionnaire. This assessment will be complemented by oncology-specific patient-reported outcomes, including the Edmonton Symptom Assessment System, European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire - Information 25, and a structured adherence questionnaire. Caregiver anxiety, depression, and burden will be assessed using the Hospital Anxiety and Depression Scale and the Zarit Burden Interview short version. The primary outcome will be patient experience, measured using Likert-scale instruments adapted from previously published comfort care and emergency department experience instruments. Secondary outcomes include staff experience, length of stay, satisfaction indicators, oncological treatment adherence, symptom control, patient understanding of disease-related information, functionality, need for re-evaluation, hospital admissions, and caregiver outcomes at 30 days.

Expected Results: The study is expected to demonstrate that a low-cost, non-pharmacological intervention can enhance the experience of older adults with cancer and multidisciplinary teams, with favorable effects on symptom control, information comprehension, treatment adherence, and 30-day clinical outcomes.

Panoramica dello studio

Stato

Non ancora reclutamento

Condizioni

Intervento / Trattamento

Tipo di studio

Interventistico

Iscrizione (Stimato)

264

Fase

  • Non applicabile

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Contatto studio

Backup dei contatti dello studio

Luoghi di studio

  • Brasile
    • São Paulo
      • São Paulo, São Paulo, Brasile, 01308050
        • Hospital Sirio Libanes
        • Contatto:

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

  • Adulto
  • Adulto più anziano

Accetta volontari sani

No

Descrizione

Inclusion Criteria:

  • Age 60 years or older.
  • Receiving care at the Oncology Center in the context of active cancer treatment: intravenous chemotherapy, supportive therapy, or clinical evaluation.
  • Capacity to provide informed consent and respond to the interview, or presence of a legal representative or companion able to do so.

Exclusion criteria.

  • Refusal to participate in the study or to use the comfort menu and cart items.
  • Decreased level of consciousness or acute clinical instability (hemodynamic instability, acute respiratory failure).
  • Absence of a companion able to consent and provide information when the patient presents cognitive impairment.
  • Inability to be contacted by telephone for the follow-up interview.

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

  • Scopo principale: Ricerca sui servizi sanitari
  • Assegnazione: Non randomizzato
  • Modello interventistico: Assegnazione parallela
  • Mascheramento: Separare

Armi e interventi

Gruppo di partecipanti / Arm
Intervento / Trattamento
Nessun intervento: Pré - Intervention
Usual Oncologic Care
Sperimentale: Post - Intervention
Comfort menu and cart implemented
Altro: Comfort menu and cart implemented

The comfort menu and cart will be implemented after the pre-intervention data collection phase.The cart will be positioned in an easily accessible area of the infusion floor, and the menu will be presented to eligible patients in printed or digital format (tablet). A one-month rollout period will precede post-intervention enrolment, dedicated to staff training and resolution of logistic challenges, in order to optimize fidelity.

Comfort cart contents: Hot and cold packs; Extra blankets and pillows; face towels; gloves and hats; Personal hygiene kit (toothbrush, toothpaste, cotton swabs, sleep mask, comb, deodorant, hand lotion); Distraction items (magazines, word-search puzzles, playing cards, coloring pages); Communication and orientation aids (reading glasses, magnifying glass, penlight, mobile phone charger, notepad, sound amplification device).

Comfort menu options (oncology-specific): Physiotherapy assessment;Conversation with chaplain, concierge, or social worker.

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Experience of older patients treated in the tertiary oncology center
Lasso di tempo: Baseline assessment during oncologic center stay

Patient experience will be assessed using the Older Adult Oncology Patient Experience Scale, composed by Likert scale items. measured by Likert-scale items, assess perceived comfort, age-specific care, communication, and respect during the index oncology center visit. Each item is scored on a 5-point LIKERT SCALE ranging 1 to 5, whwrw 1 indicates the least fevorable experience and 5 indicates the most favorable experience. Higher scores indicate a better patient experience.

In the post - intervention phase, assitional items will assess use of, and perceived value atributed, the comfort card and comfort menu. These items will also be scored on the same 5-point Likert scale randging 1 to 5, with higher scores indicating greater perceived values or satisfaction
Baseline assessment during oncologic center stay

Misure di risultato secondarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Experience of medical and multidisciplinary staff involved in caring for older patients treated in the oncologic Center
Lasso di tempo: 6 months pre and post intervention, cuncurrent with patients inclusion

The interview will fololow the standartization of the original comfort cart validation study, using the Older Adult Oncology Patient Experience Scale, composed by Likert scale items. measured by Likert-scale items, assess perceived comfort, age-specific care, communication, and respect during the index oncology center visit. Each item is scored on a 5-point LIKERT SCALE ranging 1 to 5, whwrw 1 indicates the least fevorable experience and 5 indicates the most favorable experience. Higher scores indicate a better patient experience.

In the post - intervention phase, assitional items will assess use of, and perceived value atributed, the comfort card and comfort menu. These items will also be scored on the same 5-point Likert scale randging 1 to 5, with higher scores indicating greater perceived values or satisfaction.
6 months pre and post intervention, cuncurrent with patients inclusion
Transactional Net Promoter Score
Lasso di tempo: 30 days
Institutional satisfaction will be assessed using the Transactional Net Promoter Score, calculated from the standard 0-to-10 recommendation question. Respondents scoring 9-10 will be classified as promoters, 7-8 as passives, and 0-6 as detractors. The final Transactional Net Promoter Score ranges from -100 to +100, with higher scores indicating greater institutional satisfaction.
30 days
Number of Ombudsman Manifestations Classified by Type
Lasso di tempo: 30 days
Ombudsman manifestations related to the intervention period will be classified as complaints, suggestions, or compliments. The outcome will be reported as the number of manifestations in each category during the 30-day assessment period.
30 days
Caregiver anxiety and depression symptoms
Lasso di tempo: Baselina assessment during Oncologic Center stay
Caregiver anxiety and depression symptoms will be assessed using the Hospital Anxiety and Depression Scale (HADS). The HADS includes two subscales: anxiety and depression. Each subscale ranges from 0 to 21, with higher scores indicating greater symptom severity and therefore a worse outcome.
Baselina assessment during Oncologic Center stay
Caregiver burden
Lasso di tempo: Baseline assessement using oncologic center stay
Caregiver burden will be assessed using the 12-item Zarit Burden Interview Short Form (ZBI-12). Each item is scored from 0 to 4, and the total score ranges from 0 to 48, with higher scores indicating greater caregiver burden and therefore a worse outcome.
Baseline assessement using oncologic center stay

Altre misure di risultato

Misura del risultato
Misura Descrizione
Lasso di tempo
Length of Stay Beyond Programmed Duration in the Infusion Oncology Center
Lasso di tempo: At discharge from the index Oncology Center visit
Length of stay beyond the programmed duration will be assessed during the index visit to the Infusion Oncology Center. This outcome will be calculated as the difference between the actual time spent in the Infusion Oncology Center and the programmed duration of the visit, reported in minutes.
At discharge from the index Oncology Center visit
Symptom burden
Lasso di tempo: At 30 days after the index Oncology Center visit
Symptom burden will be assessed using the Edmonton Symptom Assessment System (ESAS). Each symptom is scored from 0 to 10, where 0 indicates absence of the symptom and 10 indicates the worst possible symptom severity. The total ESAS symptom burden score will be calculated as the sum of the assessed symptom items, ranging from 0 to 90, with higher scores indicating greater symptom burden and therefore a worse outcome.
At 30 days after the index Oncology Center visit
Understanding of the information received
Lasso di tempo: At 30 days after the index Oncology Center visit
Understanding of the information received will be assessed using the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire - Information 25 (EORTC QLQ-INFO25). Scores will be transformed to a scale ranging from 0 to 100, with higher scores indicating better understanding of the information received and therefore a better outcome.
At 30 days after the index Oncology Center visit
Completion of Oncological Treatment as Planned
Lasso di tempo: 30 days after the index Oncology Center visit
Oncological treatment completion will be assessed as the proportion of patients who complete the planned oncological treatment without unplanned discontinuation during the 30-day assessment period. The outcome will be reported as the number and percentage of patients who completed treatment as planned.
30 days after the index Oncology Center visit
Functionality- Basic Activities of Daily Living Assessed by the Katz Index
Lasso di tempo: At 30 days after the index Oncology Center visit
Basic activities of daily living will be assessed using the Katz Index of Independence in Activities of Daily Living. The total score ranges from 0 to 6, with higher scores indicating greater functional independence and therefore a better outcome.
At 30 days after the index Oncology Center visit
Functionality- Basic Activities of Daily Living Assessed by the Barthel Index
Lasso di tempo: At 30 days after the index Oncology Center visit
Basic activities of daily living will be assessed using the Barthel Index of Activities of Daily Living. The total score ranges from 0 to 100, with higher scores indicating greater functional independence and therefore a better outcome.
At 30 days after the index Oncology Center visit
Functionality - Instrumenctal activities of daily living
Lasso di tempo: At 30 days after the index Oncology Center visit
Instrumental activities of daily living will be assessed using the Lawton-Brody Instrumental Activities of Daily Living Scale. In the version used in this study, total scores range from 9 to 27, with higher scores indicating better functionality and less dependence, from total dependence to mild dependence.
At 30 days after the index Oncology Center visit
Cognitive performance
Lasso di tempo: At 30 days after the index Oncology Center visit
Adressed using the 10 point cognitive screener. With a score ranging from 0 to 10, it classifies cognitive performance as normal ( > = 8) , possible cognitive impeirement (6-7), or probaple cognitive imeirement (0-5), with adjustments for education level.
At 30 days after the index Oncology Center visit
Mood symptom
Lasso di tempo: At 30 days after the index Oncology Center visit
Mood symptoms will be assessed using the Geriatric Depression Scale - 15-item version (GDS-15). The total score ranges from 0 to 15, with higher scores indicating more depressive symptoms and therefore a worse outcome.
At 30 days after the index Oncology Center visit
Clinical re-evaluations and unplanned hospital admissions
Lasso di tempo: At 30 days after the index Oncology Center visit
Number of clinical re-evaluations and unplanned hospital admissions in the 30 days following the index visit.
At 30 days after the index Oncology Center visit
Falls
Lasso di tempo: At 30 days after the index Oncology Center visit
number of falls at 30 days.
At 30 days after the index Oncology Center visit
Mortality
Lasso di tempo: At 30 days after the index Oncology Center visit
Mortality at 30 days.
At 30 days after the index Oncology Center visit
Dose Reduction Due to Toxicity
Lasso di tempo: 30 days after the index Oncology Center visit
Dose reduction due to toxicity will be assessed as the proportion of patients who require any reduction in the planned oncological treatment dose because of treatment-related toxicity during the 30-day assessment period. The outcome will be reported as the number and percentage of patients with dose reduction due to toxicity.
30 days after the index Oncology Center visit
Treatment Delay or Interruption Due to Toxicity
Lasso di tempo: 30 days after the index Oncology Center visit
Treatment delay or interruption due to toxicity will be assessed as the proportion of patients who experience any delay or interruption of oncological treatment because of treatment-related toxicity during the 30-day assessment period. The outcome will be reported as the number and percentage of patients with treatment delay or interruption due to toxicity.
30 days after the index Oncology Center visit

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Sponsor

Hospital Sirio-Libanes

Investigatori

  • Investigatore principale: Theodora Karnakis, MD, PhD, Hospital Sírio-Libanês

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio (Stimato)

20 agosto 2026

Completamento primario (Stimato)

20 settembre 2027

Completamento dello studio (Stimato)

20 ottobre 2027

Date di iscrizione allo studio

Primo inviato

10 giugno 2026

Primo inviato che soddisfa i criteri di controllo qualità

23 giugno 2026

Primo Inserito (Effettivo)

26 giugno 2026

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Effettivo)

26 giugno 2026

Ultimo aggiornamento inviato che soddisfa i criteri QC

23 giugno 2026

Ultimo verificato

1 giugno 2026

Maggiori informazioni

Termini relativi a questo studio

Parole chiave

Termini MeSH pertinenti aggiuntivi

Altri numeri di identificazione dello studio

  • AVAP-NG 3776-B

Piano per i dati dei singoli partecipanti (IPD)

Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?

NO

Descrizione del piano IPD

Patient Confidentialy

Informazioni su farmaci e dispositivi, documenti di studio

Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti

No

Studia un dispositivo regolamentato dalla FDA degli Stati Uniti

No

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .

Prove cliniche su Confort

Prove cliniche su Comfort menu and cart implemented

Cerca prove simili

Sponsor e collaboratori

Condizioni mediche

Interventi farmacologici

CROs by country

CROs in Congo, DR of

Condizioni

Malattie rare

Interventi farmacologici

Supplementi dietetici

Sponsor / Collaboratori

Sedi

3
Sottoscrivi